INDIANAPOLIS, IN, September 30, 2026 /24-7PressRelease/ -- Lauren Geary has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Geary has established herself as an expert in global regulatory scientific communications and clinical safety data standardization, earning recognition for her leadership and technical acumen. In her current capacity as senior director of regulatory submissions and capabilities at Eli Lilly and Company, she is responsible for training medical writers on global regulatory guidance, operationalizing efficiency and standardization in global scientific communications, and leading efforts to improve clarity and accuracy in regulatory submissions.

Dr. Geary's most notable achievement at Eli Lilly and Company has been developing a unified map that connects dozens of previously disconnected global regulatory guidelines, agency review practices, and data standards for reporting clinical trial data. In 2026, the methodology was disclosed in a publication in the Drug Information Association-affiliated journal Therapeutic Innovation & Regulatory Science and was presented to industry at the 2026 Drug Information Association's global annual meeting. This initiative addressed a longstanding gap that even regulatory agencies had struggled to close, generating significant excitement across the industry among agencies, technology vendors and pharmaceutical sponsors. The project laid essential groundwork for more accurate and consistent clinical trial data reporting. Such groundwork will advance human understanding and the ability to develop artificial intelligence tools to automate aspects of the reporting process.

From 2021 to 2025, Dr. Geary served as associate director of global scientific communications (regulatory medical writing) at Eli Lilly and Company, where she was responsible for compiling clinical trial data for submissions to regulatory agencies and was instrumental in shaping the company's approach to advancing global submissions.

From 2017 to 2019, Dr. Geary served as a technical writer in quality affairs at The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., where she contributed to the foundation's mission by ensuring the accuracy and compliance of technical documentation. Between 2015 and 2017, she was a postdoctoral fellow at The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., engaging in advanced research projects that built on her academic training, including conducting research into a more effective dengue virus vaccine adjuvant. In 2014, she worked as a postdoctoral scholar research associate at the University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences.

Dr. Geary's foundational experience began as a graduate research assistant at the Keck School of Medicine of the University of Southern California from 2007 to 2013, where she conducted research that led to the identification of a drug candidate. Prior to this, she was an intern and junior technician step I at the Joan and Sanford I. Weill School of Veterinary Medicine — part of the University of California, Davis — from 2003 to 2007.

Dr. Geary's academic achievements have played a pivotal role in her career trajectory. She earned a Doctor of Philosophy from the Keck School of Medicine at the University of Southern California in Los Angeles in 2013 after completing coursework toward a combined Doctor of Philosophy/Doctor of Medicine track. She received a Bachelor of Science in genetics from the University of California, Davis, in 2006.

Additionally, Dr. Geary has obtained several certifications that have enhanced her expertise in laboratory practices and clinical research methodologies. She completed certification in good laboratory practices regulation under Title 21 Code of Federal Regulations Part 58 at the University of Southern California in 2014.

In 2015, Dr. Geary earned certifications in clinical trial designs for emerging infectious diseases and non-microbial biomarkers of infection for in vitro diagnostic device use from the United States Food and Drug Administration. That same year, she completed operational clinical infectious disease training through the Walter Reed Army Institute of Research and Department of Defense Global Emerging Infections Surveillance and Response Systems at Uniformed Services University. Additionally, she completed regulatory documentation training with the United States Army Materiel Command in 2015 and battlefield healthcare training with United States Army Materiel Command in 2016.

Throughout her career, Dr. Geary has been actively involved with numerous professional organizations that reflect her commitment to advancing science communication and leadership within her field. She served as a chairperson at the 2026 Drug Information Association the global annual meeting and is a member of Ragan's Communications Leadership Council, the Regulatory Affairs Professionals Society, and the Healthcare Businesswomen's Association.

Past affiliations include Toastmasters International Lilly Corporate Center, in an official role (secretary), the Association of the United States Army, the American Association for the Advancement of Science, and the American Association for Cancer Research.

Dr. Geary's dedication has earned her multiple awards throughout her career. Most recently, she received the Lilly–Syneos Health Engagement Award from Syneos Health in 2023 and was named among the Lilly Top 100 Innovators in 2021. She was included in several team achievement awards from Eli Lilly and Company, including Bioethics Excellence Awards and a Pediatric Excellence Award. She was also recognized for the impact of her graduate research with awards from the Keck School of Medicine of the University of Southern California and the American Association for Cancer Research. Earlier in her career, she received several academic honors and scholarships during her collegiate studies.

Beyond her professional pursuits, Dr. Geary volunteered with Eli Lilly and Company's Veterans Leadership Network's community outreach pillar and Women in Motion, reflecting her commitment to supporting others within her community. She credits her resilience to a childhood shaped by scientific curiosity alongside financial hardship, which instilled a strong work ethic and deep appreciation for how far she has come. She is drawn to problems others consider too complex to solve and to building teams capable of tackling them, a strength colleagues have called her superpower.

Looking ahead, Dr. Geary intends to continue connecting global regulatory guidelines so patients benefit directly through clearer drug labeling that communicates risk factors, timing considerations and monitoring needs — ultimately supporting safer prescribing decisions by clinicians. She also aspires to transition into science or regulatory policy work as a translator between scientists and government funding decision-makers, drawing on insights gained through past lobbying experience about communication gaps between researchers and legislative staff.

# # #